ASCO 2024: Is Belantamab Mafodotin Making a Comeback in the DREAMM-8 Myeloma Trial?

By: Vanessa A. Carter, BS
Posted: Monday, June 3, 2024

The phase III DREAMM-8 study, performed by Suzanne Trudel, MD, of Princess Margaret Cancer Centre, Toronto, and colleagues, compared survival outcomes with the antibody-drug conjugate belantamab mafodotin-blmf plus pomalidomide and dexamethasone (BPd) with pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed or refractory multiple myeloma. The results of this study, which met its primary endpoint of progression-free survival, were presented during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract LBA105).

“The DREAMM-8 study demonstrated a statistically significant and clinically meaningful progression-free survival benefit with BPd vs PVd in relapsed or refractory multiple myeloma with more than one prior line of therapy,” the investigators concluded. “BPd also led to deeper and more durable responses, showed a favorable overall survival trend, and had a manageable safety profile.”

This trial enrolled 302 patients with relapsed or refractory multiple myeloma who received at least one prior therapy. Participants were randomly assigned on a 1:1 basis to receive 28 cycles of BPd (n = 155) or 21 cycles of PVd (n = 147).

The median follow-up was 21.78 months. The median progression-free survival was significantly improved with BPd compared with PVd (not reached vs 12.7 months; P < .001); the 12-month progression-free survival rates were 71% and 51%, respectively. Although the objective response rate was similar between treatment arms (77% vs 72%), the rate of complete response or better was higher with BPd (40%) than with PVd (16%). 

The median duration of response was not reached among patients treated with BPd and was 17.5 months among those given PVd. The overall survival follow-up is ongoing; there appeared to be a positive trend favoring the BPd regimen. Nearly all patients in both cohorts experienced adverse events, which were reportedly manageable and consistent with the existing safety profiles of each agent.

Disclosure: For full disclosures of the study authors, visit coi.asco.org.

2024 ASCO Annual Meeting

---